NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].

Osteoclast:1.57 μM

NFATc1-IN-1（0、0.5、1.0、1.5、2.0、2.5 μM，4天）在抑制破骨细胞形成和功能方面表现出强大活性，从而导致骨吸收减少，同时在高达2.5 μM的浓度下对破骨细胞前体细胞没有表现出细胞毒性效应。NFATc1-IN-1（1.5-2.5 μM，24小时）阻断NFATc1核内转移并降低NFATc1水平。